FRUZAQLA 5 mg hard capsules

DRUG3 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Fondation Franc.Cancerologie Digestive

Conditions

Metastatic Colorectal Cancer without liver metastasesmetastatic oeso-gastric adenocarcinomamétastatique colorectal cancer

Phase 2

– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases

RecruitingCTIS2024-519929-38-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHMetastatic Colorectal Cancer without liver metastases

Start: 2025-10-27Target: 140Updated: 2025-10-27

PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer

Not yet recruitingCTIS2025-522108-26-00

Fondation Franc.Cancerologie Digestivemétastatique colorectal cancer

Target: 74Updated: 2025-10-08

Phase 3

ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.

RecruitingCTIS2025-522395-92-00

Fondation Franc.Cancerologie Digestivemetastatic oeso-gastric adenocarcinoma

Start: 2025-12-15Target: 284Updated: 2025-11-10